CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...

Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...

Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite ...

Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...

Helped in part by the hype around weight-loss drugs, both NVO and LLY have outperformed the overall S&P 500 for most of the past year. However, NVO has suffered a setback lately and recently fell ...

Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 (GLP-1) ...

Online health platforms continue to advertise access to copycat versions of blockbuster weight-loss drugs Wegovy and Zepbound ...

Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make and sell copycat versions of its blockbuster drugs for weight loss until ...

Sal Ingrassia, a CBP port director, stated that weight loss drugs such as Ozempic and Wegovy ... Price Action: NVO stock is up 2.16% at $120.07, and LLY stock is up 1.53% at $924.65 at the last ...

Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing ...

(Reuters) - Americans are still eagerly seeking prescriptions for Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO)'s weight-loss and diabetes drugs but cannot always fill them because of supply ...